This content is machine translated CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes Approximately 30–40% of patients with type 2 diabetes develop chronic kidney disease (CKD) over time. In “landmark” studies such as CREDENCE, DAPA-CKD, EMPA-KIDNEY, and several others, SGLT-2 (sodium-glucose-linked transporter 2)...…
View Post 6 min This content is machine translated Recognize CKD early and avoid dialysis Screen diabetics and hypertensive patients regularly and use modern therapies High blood pressure and diabetes are the main causes of CKD – early diagnosis and treatment can reduce the risk of kidney failure and cardiorenal complications. Regular screening of these...…
View Post 3 min This content is machine translated Diabetic kidney disease Canagliflozin approved in fast track for diabetic nephropathy Kidney protection is extremely important for diabetes sufferers. Recently, canagliflozin became the first SGLT-2 inhibitor in Switzerland to receive a marketing authorization extension to reduce the risk of progression to…
